Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.33 |
| ▸ | CDK1 | P06493 | 3/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005628 | 0.80 | LIMK1 (0.38) | LMNAFFAR2 | |
| SCHEMBL3237641 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3241299 | 0.71 | KDM4E (0.36) | KDM4EALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL11617356 | 0.71 | CHEK1 (0.40) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3236525 | 0.70 | CDK1 (0.66) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL21347895 | 0.69 | PDPK1 (0.43) | CCNB2CDK1CCNB1CCNB3FFAR2 | |
| SCHEMBL3231063 | 0.69 | CCNB2 (0.51) | KDM4EALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3234802 | 0.67 | CCNB2 (0.63) | KDM4EALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3239170 | 0.67 | CDK1 (0.63) | KMT2AMEN1LMNAMAPK1CCNB2 | |
| SCHEMBL4574090 | 0.67 | HCAR2 (0.41) | KDM4EALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294741-B1 | 5-SUBSTITUTED 7-[4-(2-PYRIDYL)PHENYLMETHYLAMINO]-3-ISO PROPYLPYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES, USE THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) | 2019-05-01 | — | — | EP | disclosed |
| US-9957273-B2 | 5-substituted 7- [4-(2-pyridyl)phenylmethylamino] -3-isopropylpyrazolo4,3-D]pyrimidine derivatives, use thereof as medicaments, and pharmaceutical compositions | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2018-05-01 | — | — | US | disclosed |
| US-20180072736-A1 | 5-SUBSTITUTED 7-[4-(2-PYRIDYL)PHENYLMETHYLAMINO]-3-ISOPROPYLPYRAZOLO4,3-D]PYRIMIDINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2018-03-15 | — | — | US | disclosed |
| WO-2016180380-A1 | 5-SUBSTITUTED 7-[4-(2-PYRIDYL)PHENYLMETHYLAMINO]-3-ISOPROPYLPYRAZOLO4,3-D]PYRIMIDINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) | 2016-11-17 | — | — | WO | disclosed |
| EP-1475094-B1 | Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use | USTAV EX BOTAN AKADEMIE VED CE (CZ) | 2010-07-28 | — | — | EP | disclosed |
| US-20070167466-A1 | \"Pyrazolo [4,3-d]pyrimidines, processes for their preparation and methods of use\ | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2007-07-19 | — | — | US | disclosed |
| WO-2004098608-A1 | PYRAZOLO [4, 3-D]PYRIMIDINES, PROCESSES FOR THEIR PREPARATION AND METHODS OF USE | ÚSTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2004-11-18 | — | — | WO | disclosed |
| EP-1475094-A1 | Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072736-A1 | 5-SUBSTITUTED 7-[4-(2-PYRIDYL)PHENYLMETHYLAMINO]-3-ISOPROPYLPYRAZOLO4,3-D]PYRIMIDINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | CDK5, CDK2, CDK4 | KDM4E 1007/4885ALDH1A1 3276/4885KMT2A 2338/4885 |
| US-20070167466-A1 | \"Pyrazolo [4,3-d]pyrimidines, processes for their preparation and methods of use\ | CBR3, PYM1, PNPO | KDM4E 2102/4885ALDH1A1 1636/4885KMT2A 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.